Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...

Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...

Q4 2024 Earnings Call Transcript March 31, 2025 Omeros Corporation beats earnings expectations. Reported EPS is $-0.54, ...

Qfitlia does not replace the missing clotting factor. Rather, it reduces the amount of a protein called antithrombin, leading ...

The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...

Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce ...

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

The FDA has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in ...

Milwaukee Bucks guard Damian Lillard is likely out indefinitely because of deep vein thrombosis in his right calf.

PARIS, France I March 28, 2025 I The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for ...

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first ...